B cells

[Scientific Reports] The authors examined the role of B-cell CLL/lymphoma 9 (BCL9), which is downstream of hypoxia-inducible factor 1α and a Wnt/β-catenin transcriptional cofactor, in the osteo/odontoblastic differentiation of human dental pulp stem cells under hypoxic conditions.

[Cytopathology] Flowcytometry of FNA/ scrape material from 30 cases of benign lymph nodes was evaluated to study the distribution of lymphoid populations and assess presence and percentages of immunophenotypic outliers.

[Nature Medicine] The authors edited the TRAC locus in human peripheral blood T cells to engage cell-surface targets through their T cell receptor–CD3 complex reconfigured to utilize the same immunoglobulin heavy and light chains as a matched CAR.

[Sana Biotechnology, Inc.] Sana Biotechnology, Inc. announced that the company entered into an agreement with the National Cancer Institution, an institute of the National Institutes of Health, for worldwide exclusive commercial rights to the NIH’s CD22 CAR with a fully-human binder for use in certain in vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies.

[Bioengineered] Scientist found ZNF267 was significantly upregulated in diffuse large B-cell lymphoma and predicted a poor survival outcome based on the bioinformatics analysis.

[Journal For Immunotherapy of Cancer] Researchers investigated how tumor-specific murine CD8+ T cells and human tumor infiltrating lymphocytes were impacted when expanded ex vivo with the TLR9 agonist CpG.